CONVERT Scientific Trial Knowledge Exhibits Preliminary Success of the Eryseal System in Sufferers with Superior COPD/Emphysema Introduced at ERS

Barcelona, ​​Spain and Redwood Metropolis, California, USA: Pulmonx Company (Nasdaq: Lung) (“Pulmonx”), a world chief in minimally invasive therapies for extreme lung illness, declares the presentation of interim outcomes from the CONVERT research on the 2022 European Respiratory Society (ERS) Worldwide Convention. Knowledge from the primary 40 sufferers within the research demonstrated that therapy … Read more